Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 11/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2178265 | 0.92 | CRHR1 (0.39) | CRHR1ALDH1A1HPGDKDM4EMAPT | |
| SCHEMBL2932988 | 0.89 | CRHR1 (0.38) | CRHR1ALDH1A1HPGDKDM4EMAPT | |
| SCHEMBL20756845 | 0.87 | CRHR1 (0.38) | CRHR1ALDH1A1HPGDKDM4EMAPT | |
| SCHEMBL2494970 | 0.86 | CRHR1 (0.38) | CRHR1ALDH1A1HPGDKDM4EMAPT | |
| SCHEMBL20756306 | 0.85 | CRHR1 (0.39) | CRHR1ALDH1A1HPGDKDM4EMAPT | |
| SCHEMBL25490375 | 0.84 | CRHR1 (0.49) | CRHR1ALDH1A1HPGDKDM4EMAPT | |
| SCHEMBL544959 | 0.83 | CRHR1 (0.40) | CRHR1ALDH1A1HPGDKDM4EMAPT | |
| SCHEMBL2182127 | 0.83 | CRHR1 (0.61) | CRHR1ALDH1A1HPGDKDM4EMAPT | |
| SCHEMBL2497119 | 0.83 | HPGD (0.35) | CRHR1ALDH1A1HPGDKDM4EMAPT | |
| SCHEMBL2931270 | 0.82 | HPGD (0.39) | CRHR1ALDH1A1HPGDKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563718-B2 | Thiazolyl-pyrazolopyrimidine compounds as synthetic intermediates and related synthetic processes | ELI LILLY AND COMPANY (US) | 2013-10-22 | — | — | US | disclosed |
| US-20110166345-A1 | THIAZOLYL-PYRAZOLOPYRIMIDINE COMPOUNDS AS SYNTHETIC INTERMEDIATES AND RELATED SYNTHETIC PROCESSES | ELI LILLY AND COMPANY (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166345-A1 | THIAZOLYL-PYRAZOLOPYRIMIDINE COMPOUNDS AS SYNTHETIC INTERMEDIATES AND RELATED SYNTHETIC PROCESSES | FDPS, DHFR, TPMT | CRHR1 4587/4885ALDH1A1 1219/4885HPGD 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.